Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1941 1
1942 1
1946 1
1947 1
1950 1
1951 2
1952 3
1953 2
1954 1
1955 1
1956 2
1957 1
1959 4
1960 1
1961 3
1962 1
1963 1
1964 1
1966 2
1967 7
1968 4
1969 5
1970 1
1971 2
1972 7
1973 2
1974 3
1975 4
1976 7
1977 6
1978 1
1979 3
1980 5
1981 7
1982 2
1983 7
1984 4
1985 7
1986 7
1987 13
1988 7
1989 11
1990 10
1991 12
1992 8
1993 4
1994 6
1995 13
1996 15
1997 16
1998 14
1999 13
2000 11
2001 7
2002 16
2003 11
2004 9
2005 10
2006 15
2007 14
2008 21
2009 16
2010 20
2011 25
2012 21
2013 30
2014 25
2015 35
2016 34
2017 34
2018 32
2019 28
2020 33
2021 40
2022 27
2023 45
2024 38
2025 50

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

823 results

Results by year

Filters applied: . Clear all
Page 1
Atopic dermatitis.
Langan SM, Irvine AD, Weidinger S. Langan SM, et al. Among authors: irvine ad. Lancet. 2020 Aug 1;396(10247):345-360. doi: 10.1016/S0140-6736(20)31286-1. Lancet. 2020. PMID: 32738956 Review.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. Among authors: irvine ad. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Atopic dermatitis.
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Weidinger S, et al. Among authors: irvine ad. Nat Rev Dis Primers. 2018 Jun 21;4(1):1. doi: 10.1038/s41572-018-0001-z. Nat Rev Dis Primers. 2018. PMID: 29930242 Review.
Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS).
Canaud G, Lopez Gutierrez JC, Irvine AD, Vabres P, Hansford JR, Ankrah N, Branle F, Papadimitriou A, Ridolfi A, O'Connell P, Turner S, Adams DM. Canaud G, et al. Among authors: irvine ad. Genet Med. 2023 Dec;25(12):100969. doi: 10.1016/j.gim.2023.100969. Epub 2023 Aug 24. Genet Med. 2023. PMID: 37634128 Free article.
The microbiome in patients with atopic dermatitis.
Paller AS, Kong HH, Seed P, Naik S, Scharschmidt TC, Gallo RL, Luger T, Irvine AD. Paller AS, et al. Among authors: irvine ad. J Allergy Clin Immunol. 2019 Jan;143(1):26-35. doi: 10.1016/j.jaci.2018.11.015. Epub 2018 Nov 23. J Allergy Clin Immunol. 2019. PMID: 30476499 Free PMC article. Review.
A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council.
Haag C, Alexis A, Aoki V, Bissonnette R, Blauvelt A, Chovatiya R, Cork MJ, Danby SG, Eichenfield LF, Eyerich K, Gooderham M, Guttman-Yassky E, Hijnen DJ, Irvine AD, Katoh N, Murrell DF, Leshem YA, Levin AA, Vittrup I, Olydam JI, Orfali RL, Paller AS, Renert-Yuval Y, Rosmarin D, Silverberg JI, Thyssen JP, Ständer S, Stefanovic N, Todd G, Yu J, Simpson EL. Haag C, et al. Among authors: irvine ad. Br J Dermatol. 2024 Dec 23;192(1):135-143. doi: 10.1093/bjd/ljae342. Br J Dermatol. 2024. PMID: 39250758 Free article.
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.
Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Burmester GR, et al. Among authors: irvine ad. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735. RMD Open. 2023. PMID: 36754548 Free PMC article. Clinical Trial.
Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis.
Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH. Palmer CN, et al. Among authors: irvine ad. Nat Genet. 2006 Apr;38(4):441-6. doi: 10.1038/ng1767. Epub 2006 Mar 19. Nat Genet. 2006. PMID: 16550169
823 results